Fidelity Investments
TELO icon

Fidelity Investments’s Telomir Pharmaceuticals TELO Stock Holding History

Fidelity Investments’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,605
Closed -$7.01K – 5608
2025
Q2 		$7.01K Buy
5,605
+4,788
+586% +$11.1K ﹤0.01% 4629
2025
Q1 		$2.64K Sell
817
-576
-41% -$2.52K ﹤0.01% 4839
2024
Q4 		$5.74K Buy
1,393
+1,249
+867% +$5.89K ﹤0.01% 4636
2024
Q3 		$924 Buy
+144
New +$702 ﹤0.01% 4914

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments's TELO Position: Q3 2025 in Review

Fidelity Investments sold out of Telomir Pharmaceuticals (TELO) in Q3 2025, closing a stake of 5,605 shares — an estimated $7.01K sold.

Fidelity Investments first reported a position in TELO in Q3 2024 and held it in 4 quarters. The position peaked at $7.01K in Q2 2025. 32 funds tracked by Wall St. Rank hold TELO as of Q3 2025.

  • Fidelity Investments reported no remaining Telomir Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Fidelity Investments sold 5,605 Telomir Pharmaceuticals shares in Q3 2025, an estimated $7.01K.
  • Fidelity Investments first reported a position in Telomir Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Fidelity Investments's Telomir Pharmaceuticals position peaked at $7.01K in Q2 2025.
  • 32 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q3 2025.

Based on Fidelity Investments's 13F filing for Q3 2025, filed 13 Nov 2025.